NAD+ Recycling
The level of NAD+ in the body isn't just about how much of the coenzyme a cell makes from scratch — it's mainly about how efficiently it reclaims NAD+ from the byproducts of its own breakdown, a process called the salvage pathway, whose efficiency declines with age regardless of how much precursor is supplied through diet or supplements.
Number of studies
4
Safety
High
Time to effects
This is a continuous metabolic process, not an intervention with a measurable time to effect — in the clinical study, improved NAMPT activity in muscle was observed after several months of regular aerobic and resistance training.
Who it's for
Table of contents
TL;DR
The level of NAD+ in the body isn't just about how much of the coenzyme a cell makes from scratch — it's mainly about how efficiently it reclaims NAD+ from the byproducts of its own breakdown, a process called the salvage pathway, whose efficiency declines with age regardless of how much precursor is supplied through diet or supplements.
- →Mechanistically explains why the age-related decline in NAD+ isn't purely a matter of 'production,' but also of rising consumption by the enzyme CD38
- →Helps explain why simply supplying precursors (e.g., via supplements) doesn't necessarily fully compensate for the declining efficiency of the whole salvage pathway
- →Points to physical training as a modifiable factor supporting NAMPT activity, documented in a human clinical study
| Type of process | Enzymatic recovery (recycling) pathway for NAD+ from nicotinamide, distinct from de novo synthesis from tryptophan |
|---|---|
| Key rate-limiting enzyme | NAMPT (nicotinamide phosphoribosyltransferase) — converts nicotinamide into NMN |
| Main 'consumer' rising with age | CD38 — an NADase that degrades both NAD+ and precursors such as NMN |
| Other NAD+ consumers | Sirtuins (metabolic regulation) and PARPs (DNA repair) |
| Difference from the NMN entry | This entry covers the biology of the salvage pathway itself, not a specific supplement supplying the substrate |
| Research level | Moderate — mechanism well documented in animal models, limited direct clinical interventions in humans |
| Modifiable factor with human evidence | Aerobic and resistance training increased NAMPT activity in the skeletal muscle of older adults in a clinical study |
Understand
Overview
Most popular discussion of NAD+ (nicotinamide adenine dinucleotide) focuses on the level itself — how much we have and how to raise it with a supplement. But NAD+ inside a cell isn't a static pool — it's a resource in constant circulation: it's continuously consumed by enzymes such as sirtuins, PARPs (involved in DNA repair), and NADases from the CD38 family, and then must be regenerated. That regeneration happens mainly not through energetically costly de novo synthesis from tryptophan, but through the so-called salvage pathway — reclaiming NAD+ from nicotinamide (NAM), a byproduct generated every time one of those enzymes consumes an NAD+ molecule. It's this cycle of consumption and recovery, not a one-time 'production' event, that determines how much functional NAD+ a cell actually has available at any given moment.
With age, this cycle loses efficiency for two independent reasons at once: the activity of the enzyme that limits the rate of recovery (NAMPT) declines, while at the same time the activity of the main NAD+ 'consumer' in tissues — the enzyme CD38 — rises, degrading both NAD+ itself and its precursors (including NMN) faster than the cell can put them to use. Studies in mice suggest that it's this age-related rise in CD38 activity, not just weakening synthesis, that is a major driver of the NAD+ decline seen in aging tissue — an important distinction, because it changes where interventions are worth looking: not only at 'topping up' the substrate, but also at limiting its excessive consumption.
It's worth clearly distinguishing this entry from the separate entries on NMN and resveratrol (see related entries) — those cover specific supplement products, sold on the promise of raising NAD+ levels by supplying substrate from outside. This entry instead covers the broader biology of the salvage pathway itself — the mechanism that determines whether a supplied (or endogenously produced) precursor actually gets efficiently converted into usable NAD+, or gets degraded before the cell can use it. That distinction has practical implications: simply supplying more precursor doesn't automatically translate into a higher, functional NAD+ level in tissue if the efficiency of the salvage pathway itself (and the rate at which it 'leaks' through CD38) remains limited.
Mechanism of action
The central, rate-limiting step of the salvage pathway is the reaction catalyzed by the enzyme NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide (NAM) — generated as a byproduct every time sirtuins, PARPs, or CD38 consume an NAD+ molecule — back into nicotinamide mononucleotide (NMN). The very same compound sold as a supplement, covered in a separate entry, is thus also produced naturally and continuously inside the cell as an intermediate of its own metabolism. In the next step, enzymes from the NMNAT family convert NMN back into full-fledged NAD+, closing the recovery loop. NAMPT activity is regulated in part by circadian rhythm and cellular energy status, linking this pathway to a broader network of metabolic sensors, including AMPK and the sirtuins — the same proteins this pathway supplies with NAD+.
Consumption runs in parallel with recovery, and it's the balance between these two processes, not raw production capacity alone, that determines the available NAD+ pool. CD38, a membrane-bound and intracellular NADase, becomes progressively more active with age in many tissues — studies in mice identified it as the main enzyme responsible for degrading both NAD+ and externally administered NMN in vivo, and its absence (in CD38 knockout mice) prevented the age-typical decline in NAD+. PARPs, activated in response to DNA damage (which accumulates with age), and the sirtuins themselves also contribute to NAD+ consumption. As a result, an aging cell faces a double problem: slower recovery due to weakened NAMPT activity, and faster consumption due to rising CD38 activity and increased repair load from PARPs — a mechanism clearly different from the simple 'production shortfall' that NAD+ precursor supplement marketing often relies on.
NAD+ consumption by consuming enzymes
Sirtuins, PARPs, and CD38 consume NAD+ in their reactions, producing nicotinamide (NAM) as a byproduct.
Conversion of NAM to NMN by NAMPT
NAMPT, the rate-limiting enzyme of the whole pathway, converts nicotinamide back into nicotinamide mononucleotide.
Conversion of NMN to NAD+ by NMNAT
Enzymes from the NMNAT family close the recovery loop, converting NMN into NAD+ ready for reuse.
Rising competition from CD38 with age
CD38 activity rises with age and degrades NAD+ and its precursors faster than the cell can recover them, tilting the balance against the available coenzyme pool.
Evidence: moderate — based on 4 studies in this database.
Benefits
Common myths
MythTaking NMN or NR is the same thing as improving NAD+ recycling.
FactThese supplements supply substrate (precursor) from outside, but don't directly repair the age-related decline in NAMPT activity or curb rising degradation by CD38 — these are separate phenomena that can partly offset the effect of supplementation alone.
MythThe age-related decline in NAD+ is purely due to lower production of the coenzyme.
FactStudies in animal models suggest that rising NAD+ consumption by the enzyme CD38 with age plays a significant, possibly dominant role, not just weakening synthesis — mice lacking the CD38 gene did not show the typical age-related NAD+ decline.
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
The NMN entry covers a specific supplement — a compound sold on the promise of raising NAD+ levels. This entry covers the broader biology of the pathway that determines whether a supplied (or endogenously produced) precursor actually gets efficiently converted into usable NAD+, rather than focusing on the supplement product itself.
These supplements supply substrate from outside, which is a separate question from the efficiency of the recovery mechanism itself. If CD38 activity remains high, some of the supplied or produced precursor may be degraded before it's converted into functional NAD+ — so supplying substrate alone doesn't guarantee an improvement in the efficiency of the whole pathway.
CD38 is an enzyme (an NADase) present on the surface and inside many cell types, whose activity rises with age and which degrades both NAD+ and its precursors, including NMN. Studies in mice identified it as the main 'consumer' responsible for the age-related decline in NAD+, making it a target of interest for researchers looking to slow this process, though selective interventions targeting CD38 in humans remain at an early research stage.
Yes, and this is one of the few aspects of this pathway with direct confirmation in humans — in a clinical study, aerobic and resistance training increased NAMPT content in skeletal muscle, with a more pronounced effect in older than in younger participants.
CD38 inhibitors are the subject of active preclinical and early clinical research in the context of NAD+ metabolism, but this remains an experimental area at this stage — there's no approved pharmacological intervention yet that selectively targets CD38 for the purpose of slowing aging.
What to combine with
Good combinations
NMN (Nicotinamide Mononucleotide) — NMN is a direct substrate of this same salvage pathway — supplementation supplies precursor, but doesn't change the efficiency of the NAMPT/CD38 mechanism itself
resveratrol — Theoretical complementarity: resveratrol is studied as a potential sirtuin activator — enzymes that depend on the NAD+ reclaimed through this pathway
Mitophagy — Mitochondrial fitness and NAD+ availability (via the sirtuin SIRT3) are mechanistically linked in aging research
Safety
Side effects & contraindications
Possible side effects
Contraindications
No significant contraindications at typical doses.
Is it worth taking?
Who it's for
- People interested in the biology of NAD+ metabolism beyond precursor supplementation alone
- People who want to understand the difference between 'supplying substrate' and the efficiency of the mechanism that processes it
Not for
- No significant contraindications at typical doses.
Evidence
Worth knowing
Studies in mice identified CD38 as the main enzyme responsible for degrading externally administered NMN in vivo, not just NAD+ itself.
NAMPT, the key enzyme of the salvage pathway, is the very same enzyme that endogenously produces NMN inside the cell — long before that compound became known as a supplement.
In a clinical study, aerobic and resistance training restored NAMPT activity in older adults' muscle to a level closer to that of younger participants.
Studies
CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism
Moderate evidenceCamacho-Pereira J, Tarragó MG, Chini CCS, et al. · Cell Metabolism · 2016
A mouse study identifying CD38 as the main enzyme responsible for the age-related degradation of NAD+ and externally administered NMN — CD38 knockout mice did not show the typical NAD+ decline.
View studyNAD+ metabolism and its roles in cellular processes during ageing
Moderate evidenceCovarrubias AJ, Perrone R, Grozio A, Imai SI. · Nature Reviews Molecular Cell Biology · 2021
A comprehensive review systematizing knowledge of NAD+ metabolism, including the salvage pathway, the roles of NAMPT and CD38, and links between declining NAD+ and age-related disease.
View studyTherapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Moderate evidenceRajman L, Chwalek K, Sinclair DA. · Cell Metabolism · 2018
A review of in vivo evidence on NAD+-boosting compounds, distinguishing supplying precursors from the efficiency of NAD+ metabolism itself.
View studyAerobic and resistance exercise training reverses age-dependent decline in NAD+ salvage capacity in human skeletal muscle
Moderate evidencede Guia RM, Agerholm M, Nielsen TS, et al. · Physiological Reports · 2019
A human clinical study showing that aerobic and resistance training increases NAMPT content in skeletal muscle, reversing part of the age-related decline in NAD+ recovery capacity.
View studySources & bibliography
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
121 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
174 publications on this site
Related entries
4.1NMN (Nicotinamide Mononucleotide)
An NAD+ precursor intensively studied in the context of cellular aging — human data are still early, despite huge market popularity.
3.9Resveratrol
The red-grape polyphenol famed as a 'sirtuin activator' — but its bioavailability in humans is very low, which limits the practical relevance of many striking test-tube results.
4.0Mitophagy
A selective form of autophagy in which the cell recognizes and removes specifically damaged, dysfunctional mitochondria — a mitochondrial quality-control mechanism whose efficiency declines with age and is studied in the context of neurodegenerative disease.
4.0UPRmt
The mitochondrial unfolded protein response (UPRmt) is an intracellular repair program that protects mitochondria from stress — linked to lifespan extension in model organisms, though the relationship turned out to be more complex than initially thought.
4.3Autophagy
An intracellular 'housekeeping' process that clears out damaged proteins and organelles, whose discovery earned a Nobel Prize — one of the key mechanisms studied in the context of slowing aging.
4.3Inflammaging
Chronic, low-grade, systemic inflammation that accompanies aging even without an active infection — a term coined in 2000 by Claudio Franceschi, today considered one of the fundamental mechanisms linking aging to age-related disease.
4.2TFEB
The transcription factor TFEB acts as a master on-off switch for autophagy and the production of new lysosomes in the cell — one of the best-characterized molecular nodes linking these two processes, studied as a potential target for interventions in aging.
Related articles
PoradnikiNMN vs NAD+ vs Resveratrol — What Actually Extends Life?
Three of the biggest names in longevity, one shared hypothesis, and a very different level of evidence in humans for each. An honest comparison of mechanism, clinical trial quality, and monthly cost — with no marketing rounding up.
August 20, 2026
Badania naukoweWhat we now know about NMN and longevity — a review of human studies
NMN, a precursor of NAD+, has for years been one of the most hotly debated supplements in the biohacking community. We look at what the latest clinical trials in humans show, as distinct from earlier studies in mice.
August 11, 2026
Badania naukoweLongevity Vitamins: Which Supplements Actually Have Real Scientific Evidence Behind Them
Every supplement shelf promises a longer life in every capsule, but the hard data from large clinical trials tells a far more measured story. We go through which vitamins genuinely extend healthy lifespan in people with a real deficiency, and which — despite their popularity — have no supporting evidence at all, or worse, evidence of no benefit.
August 20, 2026
PoradnikiVitamin D3 and Longevity — Does a Deficiency Shorten Your Life?
Low vitamin D levels correlate with higher mortality across dozens of observational studies, yet the massive randomized VITAL trial found no evidence that supplementation extends life in people without a deficiency. We break down this apparent contradiction piece by piece.
August 20, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.